Smartkarma AI, Smartkarma

αSK

Smartkarma AI

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
 <li>
<a href="https://smartkarma.com/entities/avacta-group-plc">Avacta</a> is transitioning into a pure-play oncology biotechnology company, centered on its proprietary pre|CISION™ and Affimer® platforms, designed to improve the safety and efficacy of cancer therapies.</li>
 <li>The lead asset, AVA6000, a tumor-activated doxorubicin, has demonstrated a favorable safety profile and promising anti-tumor activity in its Phase 1 clinical trials, particularly in salivary gland cancer, providing clinical proof-of-concept for the pre|CISION™ platform.</li>
 <li>The company is strategically divesting its diagnostics division to extend its cash runway and focus resources on advancing its oncology pipeline, which includes next-generation peptide drug conjugates (PDCs) and Affimer® drug conjugates (AffDCs).</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
Avacta is transitioning into a pure-play oncology biotechnology company, centered on its proprietary pre|CISION™ and Affimer® platforms, designed to improve the safety and efficacy of cancer therapies.
  The lead asset, AVA6000, a tumor-activated doxorubicin, has demonstrated a favorable safety profile and promising anti-tumor activity in its Phase 1 clinical trials, particularly in salivary gland cancer, providing clinical proof-of-concept for the pre|CISION™ platform.
  The company is strategically divesting its diagnostics division to extend its cash runway and focus resources on advancing its oncology pipeline, which includes next-generation peptide drug conjugates (PDCs) and Affimer® drug conjugates (AffDCs).
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

iFOREX Financial Trading / Equity Bottom-Up

<ul>
<li>Updated 10th June: iFOREX Financial Trading, the fintech business with a proprietary online and mobile trading platform for multi-asset contracts for difference, announced that its proposed IPO onto the Main Market, which was expected to occur in late June, will be briefly delayed.</li>
<li>A routine thematic compliance inspection commenced earlier this year in the BVI, which was disclosed in the Company's Registration Document, requires additional time to enable finalisation ahead of the IPO.</li>
<li>The inspection process is close to completion and the Company anticipates only a short delay to the IPO timetable. </li>
</ul>


Updated 10th June: iFOREX Financial Trading, the fintech business with a proprietary online and mobile trading platform for multi-asset contracts for difference, announced that its proposed IPO onto the Main Market, which was expected to occur in late June, will be briefly delayed.
A routine thematic compliance inspection commenced earlier this year in the BVI, which was disclosed in the Company's Registration Document, requires additional time to enable finalisation ahead of the IPO.
The inspection process is close to completion and the Company anticipates only a short delay to the IPO timetable. 


Research from Hardman & Co, Hardman & Co

Hardman & Co

Research from Hardman & Co

Investment research on quoted companies and funds

Hardman & Co is a multi-disciplinary financial consultancy and investment research firm, employing highly experienced analysts and professionals with a broad range of capital markets expertise. Our clients are public and private businesses as well as fund managers, ranging from start-ups to £1 billion+ market capitalisations. Hardman & Co offers corporate research & consultancy, serving the needs of both public and private companies. We produce gold-standard research with a global reach for trading and investment companies, as well as providing market commentary and analysis. In addition, we carry out a number of bespoke investment-related assignments, including due diligence on bond listings, assessments of private company valuations and other corporate advisory services. We engage with the market through traditional and digital media, offering illuminating video content on corporate management strategy, results communication, interviews and in-house sector discussion.

Oxford Nanopore Technologies / Equity Bottom-Up

<ul><li>Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets.</li><li>Many of the 53 constituents of the index are high-risk, with micro-capitalisations and a long way from profitability.</li><li>Despite this, some companies can still make extremely attractive returns for investors.</li></ul>

Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets.Many of the 53 constituents of the index are high-risk, with micro-capitalisations and a long way from profitability.Despite this, some companies can still make extremely attractive returns for investors.

Thematic (Sector/Industry)

<ul>
<li>The Hardman &amp; Co Healthcare Index (HHI) has been running since 2009.</li>
<li>Its main function is to highlight the attractions of life sciences investments over the long term.</li>
<li>For the third year running, despite generally good returns in global markets, particularly in the US, performance in 2024 was poor, not helped by the capital-intensive nature of the sector.</li>
</ul>


The Hardman &amp; Co Healthcare Index (HHI) has been running since 2009.
Its main function is to highlight the attractions of life sciences investments over the long term.
For the third year running, despite generally good returns in global markets, particularly in the US, performance in 2024 was poor, not helped by the capital-intensive nature of the sector.


Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences

Leading International Investment Research, Edison Investment Research

Edison Investment Research

Leading International Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison Investment Research is terminating coverage on Avacta Group (AVCT), BCI Minerals (BCI), Destiny Pharma (DEST), Globalworth Real Estate Investments (GWI), Henderson Alternative Strategies Trust (HAST), Herantis Pharma (HRTIS), Jupiter Green Investment Trust (JGC) and Rockhopper Exploration (RKH). Please note you should no longer rely on any previous research or estimates for these companies. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website

Edison Investment Research is terminating coverage on Avacta Group (AVCT), BCI Minerals (BCI), Destiny Pharma (DEST), Globalworth Real Estate Investments (GWI), Henderson Alternative Strategies Trust (HAST), Herantis Pharma (HRTIS), Jupiter Green Investment Trust (JGC) and Rockhopper Exploration (RKH). Please note you should no longer rely on any previous research or estimates for these companies. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website


United Kingdom

Avacta Group plc researches, develops, produces, and delivers instrumentation and services for the biopharmaceutical drug development and clinical diagnostics markets using biophysical technology in the United Kingdom and internationally. It operates through two segments, Animal Health and Life Sciences. The Animal Health segment provides tools and contract services to assist the diagnosis of conditions in animals to enable treatment for veterinarians. The Life Sciences segment offers reagents and arrays for diagnostics, drugs, and biomarkers discovery in biotech research and development. The company was incorporated in 2003 and is based in Wetherby, the United Kingdom.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Avacta (AVCT LN)

Primer: Avacta (AVCT LN) - Oct 2025

Avacta is transitioning into a pure-play oncology biotechnology company, centered on its proprietary pre|CISION™ and Affimer® platforms,...

αSK

Hybridan Small Cap Feast: 19/06/2025

The Company reports the IPO has received strong investor interest and based on firm orders received to date, the institutional offer is heavily...

Hybridan

Hardman & Co Monthly: January 2025

Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to...

Hardman & Co

Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences

The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments...

Hardman & Co

Avacta Group - Termination of coverage

Edison Investment Research is terminating coverage on Avacta Group (AVCT), BCI Minerals (BCI), Destiny Pharma (DEST), Globalworth Real Estate...

Edison Investment Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)